Needham initiated coverage of Inari Medical with a Buy rating and $72 price target. The analyst is positive on the company’s position as a leader in the large and underpenetrated venous thrombectomy market, noting that its new product launches, international expansion, and the LimFlow acquisition should sustain strong growth for Inari Medical. Needham adds that it sees rapid improvement in the company’s operating margin and EPS in 2025 and beyond while noting that its valuation is attractive considering its high teens or better revenue growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NARI:
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
- Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
- Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M
- Inari Medical sees Q4 revenue at least $132M, consensus $130.98M
- Inari Medical price target raised to $70 from $65 at Truist